Researchers intended to see how the treatments will affect metastatic colorectal cancer patients with microsatellite stable tumors.
Here’s what you should know.
1. The companies are collaborating on a phase 1/2 study.
2. The results will determine recommended dose regimens. Researchers are hoping the treatments produce preliminary anti-tumor activity.
3. The companies want to begin the study in late 2017.
4. The companies will use the study results to propel further research.
More articles on gastroenterology:
Craig Campbell to hold ‘Cornhole Challenge’ for Fight Colorectal Cancer — 3 insights
GI leader to know: Dr. Adrienne Scheich of Ann & Robert H. Lurie Children’s Hospital
American Cancer Society Nutrition and Physical Activity guidelines increases colon cancer survival rates — 3 notes
